Halozyme Therapeutics, Inc. (NASDAQ:HALO)
CAPS Rating:
A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.
RSS Headlines
Fool UK
Recs
Tons of potential and partnerships already with roche and baxter. Look for more partnerships and revenue to start flowing in...now alot of downside on this stock for the new future.